Recurrent High Grade Glioma Treated by LITT

Inclusion Criteria: 1. Aged 18 years old or above; 2. Patients with previous pathological diagnosis of 2021 World Health Organization Classification of Central Nervous System Tumors (WHO CNS5) grade 3 or 4 glioma and received standard treatment; 3. Meet any of the following: 1. Meets the disease progression criteria in the Response Evaluation of Neuro-Oncology (RANO 2.0) criteria; 2. At least one image other than T1 contrast indicates progression; 3. Pathology shows progression or recurrence; 4. Other progress determined by the Clinical Events Committee (CEC); 4. All tumor lesions are located supratentorial and the maximum cross-sectional short-axis length in the T1 contrast is ≤30 mm; 5. Karnofsky score (KPS) ≥ 60 and the patient can tolerate the intervention; 6. The subjects or their agent can understand the purpose of the trial, show sufficient compliance with the trial protocol, and sign the informed consent form. Exclusion Criteria: 1. Patients may benefit from other treatments or may not benefit from this trial; 2. No more than three months since the patient underwent craniotomy; 3. MRI contrast cannot be performed; 4. Severe coagulation disorder; 5. Women who are pregnant, lactating, or planning to become pregnant within 6 months; 6. Participated in any other clinical trials of drugs or medical devices within 3 months; 7. Combined diseases that may interfere with treatment or prognosis assessment; 8. Refuse or unlikely to complete follow-up assessment; 9. Other circumstances in which the researcher deems it inappropriate to participate in this clinical trial.